Walubo, A <br/><br/>
RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity.  [electronic resource] 

 -  Methods and findings in experimental and clinical pharmacology  Sep 2006 
 - 423-31 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0379-0355 
<br/><br/><label>Standard No.: </label>10.1358/mf.2006.28.7.1003580  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Alanine Transaminase--blood<br/>Animals<br/>Anti-HIV Agents--administration & dosage<br/>Aryl Hydrocarbon Hydroxylases--antagonists & inhibitors<br/>Aspartate Aminotransferases--blood<br/>Chemical and Drug Induced Liver Injury--etiology<br/>Cytochrome P-450 CYP2B1--antagonists & inhibitors<br/>Cytochrome P-450 CYP3A--biosynthesis<br/>Cytochrome P-450 CYP3A Inhibitors<br/>Dexamethasone--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Enzyme Induction--drug effects<br/>Intubation, Gastrointestinal<br/>Ketoconazole--pharmacology<br/>Liver--drug effects<br/>Liver Function Tests--methods<br/>Male<br/>Nevirapine--administration & dosage<br/>Rats<br/>Rats, Sprague-Dawley<br/>Steroid Hydroxylases--antagonists & inhibitors<br/>Thiotepa--pharmacology<br/>Time Factors